Elite in Acute Myeloid Leukemia (AML)
Check Dr. Richard M. Stone's experience treating your condition:
About Dr. Richard M. Stone

Richard Stone is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Stone has been practicing medicine for over 42 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 39 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Stone is currently accepting new patients.

His clinical research consists of co-authoring 837 peer reviewed articles and participating in 16 clinical trials in the past 15 years. In particular, he has co-authored 266 articles and participated in 14 clinical trials in the study of Acute Myeloid Leukemia (AML).


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Richard M. Stone it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
450 Brookline Ave, Boston, MA 02215
Background & Education
Graduate Institution
Harvard Medical School, 1981
Hematology Oncology
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
Brigham And Womens Hospital
Dana Farber Cancer Institute
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
A Phase 1 Study of LY3214996, an ERK1/2 Inhibitor, in Patients With AML Who Are Not Candidates for Standard Therapy
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Phase 1b Study of Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve Subjects With Acute Myelogenous Leukemia
A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Multicenter Study of 9-AC in Refractory Leukemia
High-Dose Ara-C Followed by Continuous Infusion Interleukin-2 for Acute Myelogenous Leukemia in First Remission
A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
View 13 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors